

YR0036

Leader in Biomolecular Solutions for Life Science



Human RANKL Monoclonal Antibody

Catalog No.: YR0036

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Denosumab Biosimilar

Isotype

Human IgG2 kappa

Immunogen

Human RANK Ligand

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG2 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 5.2

Contact



www.abclonal.com

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)